AxioMed will also be conducting a post-market study of the device’s treatment of cervical degenerative disc disease, and the results are expected to be used in a future Investigational Device Exemption to the FDA.
More Articles on Devices:
Dr. Jason Highsmith Performed First Precision Spectra Spinal Cord Stimulator Implant
Legislation to Repeal 2.3% Medical Device Tax Introduced in Senate
Smith & Nephew Profits Up 1% in 4Q, Revenue Dips 3%
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.